Rocket Pharmaceuticals, Inc.

NasdaqGM:RCKT Stock Report

Market Cap: US$353.9m

Rocket Pharmaceuticals Valuation

Is RCKT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of RCKT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: RCKT ($3.27) is trading below our estimate of future cash flow value ($35.35)

Significantly Below Future Cash Flow Value: RCKT is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RCKT?

Key metric: As RCKT is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for RCKT. This is calculated by dividing RCKT's market cap by their current book value.
What is RCKT's PB Ratio?
PB Ratio1.1x
BookUS$313.67m
Market CapUS$353.89m

Price to Book Ratio vs Peers

How does RCKT's PB Ratio compare to its peers?

The above table shows the PB ratio for RCKT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average54.9x
TARA Protara Therapeutics
2.6x21.06%US$348.9m
AURA Aura Biosciences
2.3x8.73%US$353.7m
ANL Adlai Nortye
44.3xn/aUS$350.9m
GLSI Greenwich LifeSciences
170.3x68.07%US$372.0m
RCKT Rocket Pharmaceuticals
1.1x18.70%US$353.9m

Price-To-Book vs Peers: RCKT is good value based on its Price-To-Book Ratio (1.1x) compared to the peer average (54.9x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does RCKT's PB Ratio compare vs other companies in the US Biotechs Industry?

64 CompaniesPrice / BookEstimated GrowthMarket Cap
NKTX Nkarta
0.4x-2.70%US$139.93m
XBIT XBiotech
0.4xn/aUS$74.69m
ETHZ ETHZilla
0.1xn/aUS$66.16m
PMVP PMV Pharmaceuticals
0.5x2.71%US$59.06m
RCKT 1.1xIndustry Avg. 2.6xNo. of Companies70PB0246810+
64 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: RCKT is good value based on its Price-To-Book Ratio (1.1x) compared to the US Biotechs industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is RCKT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RCKT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RCKT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RCKT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.27
US$7.65
+133.94%
50.63%US$16.00US$2.00n/a10
Feb ’27US$3.48
US$7.65
+119.83%
50.63%US$16.00US$2.00n/a10
Jan ’27US$3.51
US$7.95
+126.63%
45.52%US$16.00US$2.00n/a11
Dec ’26US$3.16
US$7.95
+151.73%
45.52%US$16.00US$2.00n/a11
Nov ’26US$3.77
US$7.96
+111.10%
44.46%US$16.00US$2.00n/a12
Oct ’26US$3.16
US$7.85
+148.30%
45.23%US$16.00US$2.00n/a13
Sep ’26US$3.28
US$7.86
+139.55%
43.52%US$16.00US$2.00n/a14
Aug ’26US$2.99
US$8.37
+179.82%
54.44%US$19.00US$2.00n/a15
Jul ’26US$2.59
US$9.03
+248.78%
53.57%US$19.00US$2.00n/a15
Jun ’26US$2.51
US$11.03
+339.57%
70.33%US$34.00US$2.00n/a15
May ’26US$7.86
US$40.27
+412.30%
21.89%US$55.00US$29.00n/a15
Apr ’26US$5.81
US$41.60
+616.01%
20.84%US$55.00US$29.00n/a15
Mar ’26US$9.45
US$40.93
+333.11%
21.35%US$55.00US$29.00n/a14
Feb ’26US$10.74
US$43.07
+300.99%
26.87%US$65.00US$29.00US$3.4815
Jan ’26US$12.57
US$43.50
+246.06%
25.92%US$65.00US$29.00US$3.5116
Dec ’25US$14.39
US$46.79
+225.13%
21.50%US$65.00US$29.00US$3.1614
Nov ’25US$16.98
US$47.50
+179.74%
20.33%US$65.00US$31.00US$3.7714
Oct ’25US$17.12
US$47.15
+175.43%
20.98%US$65.00US$31.00US$3.1613
Sep ’25US$18.85
US$47.15
+150.15%
20.98%US$65.00US$31.00US$3.2813
Aug ’25US$22.23
US$47.38
+113.16%
19.35%US$65.00US$31.00US$2.9913
Jul ’25US$20.66
US$49.62
+140.15%
15.01%US$65.00US$37.00US$2.5913
Jun ’25US$21.32
US$50.08
+134.88%
14.28%US$65.00US$39.00US$2.5113
May ’25US$22.53
US$50.31
+123.29%
14.36%US$65.00US$39.00US$7.8613
Apr ’25US$26.72
US$51.25
+91.80%
13.09%US$65.00US$39.00US$5.8112
Mar ’25US$30.53
US$51.25
+67.87%
13.09%US$65.00US$39.00US$9.4512
Feb ’25US$29.18
US$51.17
+75.35%
14.29%US$65.00US$37.00US$10.7412
US$7.65
Fair Value
57.3% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/16 14:49
End of Day Share Price 2026/02/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rocket Pharmaceuticals, Inc. is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Whitney IjemCanaccord Genuity
Joshua SchimmerCantor Fitzgerald & Co.